RT Journal Article
T1 Targeting Protein Kinase C in Glioblastoma Treatment
A1 Geribaldi-Doldán, Noelia
A1 Hervás-Corpión, Irati
A1 Gómez-Oliva, Ricardo
A1 Domínguez-García, Samuel
A1 Ruiz, Félix A.
A1 Iglesias-Lozano, Irene
A1 Carrascal, Livia
A1 Pardillo-Díaz, Ricardo
A1 Gil-Salú, José L.
A1 Nunez-Abades, Pedro
A1 Valor, Luis M.
A1 Castro, Carmen
K1 Glioblastoma
K1 Protein kinase C
K1 Glioma stem cells
K1 Neurogenesis
K1 Neural stem cells
K1 Temozolomide
K1 Enzastaurin
K1 Epidermal growth factor receptor
K1 Neuregulin
K1 Brain tumor
K1 Apoptosis
K1 Cell cycle
K1 Proteína quinasa C
K1 Células madre
K1 Neurogénesis
K1 Células-madre neurales
K1 Temozolomida
K1 Receptores ErbB
K1 Neurregulinas
K1 Neoplasias encefálicas
K1 Ciclo celular
AB Glioblastoma (GBM) is the most frequent and aggressive primary brain tumor and is associated with a poor prognosis. Despite the use of combined treatment approaches, recurrence is almost inevitable and survival longer than 14 or 15 months after diagnosis is low. It is therefore necessary to identify new therapeutic targets to fight GBM progression and recurrence. Some publications have pointed out the role of glioma stem cells (GSCs) as the origin of GBM. These cells, with characteristics of neural stem cells (NSC) present in physiological neurogenic niches, have been proposed as being responsible for the high resistance of GBM to current treatments such as temozolomide (TMZ). The protein Kinase C (PKC) family members play an essential role in transducing signals related with cell cycle entrance, differentiation and apoptosis in NSC and participate in distinct signaling cascades that determine NSC and GSC dynamics. Thus, PKC could be a suitable druggable target to treat recurrent GBM. Clinical trials have tested the efficacy of PKCβ inhibitors, and preclinical studies have focused on other PKC isozymes. Here, we discuss the idea that other PKC isozymes may also be involved in GBM progression and that the development of a new generation of effective drugs should consider the balance between the activation of different PKC subtypes.
PB MDPI
YR 2021
FD 2021-04-04
LK http://hdl.handle.net/10668/4420
UL http://hdl.handle.net/10668/4420
LA en
NO Geribaldi-Doldán N, Hervás-Corpión I, Gómez-Oliva R, Domínguez-García S, Ruiz FA, Iglesias-Lozano I, et al. Targeting Protein Kinase C in Glioblastoma Treatment. Biomedicines. 2021 Apr 4;9(4):381
DS RISalud
RD Apr 8, 2025